"The Buzz" Show: Reata Pharmaceuticals, Inc. (NASDAQ: RETA) FDA Requests Preliminary Drug Meeting | Financial Buzz"The Buzz" Show: Reata Pharmaceuticals, Inc. (NASDAQ: RETA) FDA Requests Preliminary Drug Meeting
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Reata Pharmaceuticals, Inc. Surges as FDA Requests Preliminary Drug Meeting” Reata Pharmaceuticals, Inc. (NASDAQ: RETA) surged over 13% in premarket trading after the company announced that the FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia. The Division of Neurology Products 1 of the U.S. FDA suggested that the Company withdraw the current meeting request for a Type C meeting and instead request a pre-NDA meeting, which the Division will...
Source: financialbuzz.com